Videos

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in care decisions.

The discussion will explore the impact of fixed-duration treatments on quality of life, benefits and challenges compared with continuous therapy, financial considerations, and lifestyle goals during and after treatment.

At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.

The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.

The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

The discussion will cover the current CLL treatment landscape, including first-line and later-line options; the medical experts will review first-line treatments, approach to treatment selection, factors influencing recommendations, and strategies for shared decision-making with patients.

Medical experts explain CLL’s slow progression and its impact on treatment timing, and they also discuss the watch-and-wait approach, patient concerns, and how to address anxiety about delaying treatment.

Dr. Partow Kebriaei explains what patients can expect before, during and after an allogeneic stem cell transplant to treat acute lymphoblastic leukemia.

For patients with MDS, close monitoring by doctors may help determine the appropriate timing to undergo stem cell transplants before the disease worsens.

Jim Plotkin shares his personal experience with CLL, including his initial symptoms, the diagnostic process, challenges faced, and advice for patients with newly diagnosed CLL. Medical experts discuss their approach to explaining CLL to new patients and inquire about essential patient education resources.

Medical experts provide an overview of chronic lymphocytic leukemia (CLL), including its typical symptoms and diagnostic process. They also will inquire about key prognostic factors and their impact on patient care.

Patients who have a higher risk of head and neck cancer recurrence can expect more — and sooner — monitoring of their disease.

The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.

One expert explained why chronic lymphocytic leukemia is erroneously considered a ‘good cancer.’

From social work to cardio-oncology, there is a wide array of resources potentially available to patients, as one expert explained.

One expert explains why most of the time clinical trial enrollment is ‘the correct answer’ for patients.

There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon.

Experts discuss unmet needs and challenges faced by patients with uveal melanoma. This program was made possible with support from Immunocore.

Nathan L. Scott, M.D., discusses the safety and efficacy of tebentafusp. This program was made possible with support from Immunocore.

Nathan L. Scott, M.D., provides a brief overview of the current guidelines for treatment of metastatic uveal melanoma, as well as what considerations go into choosing the appropriate treatment for it. This program was made possible with support from Immunocore.

Nathan L. Scott, M.D., discusses the risk of recurrence within diagnosed uveal melanoma patients. Uveal Melanoma Prognosis and Risk Stratification

Nathan L. Scott, M.D., details what tests a patient should expect if they wish to confirm a uveal melanoma diagnosis. This program was made possible with support from Immunocore.

Melody Burchett discusses how she educates patients who have been recently diagnosed with uveal melanoma. Resources for Patients With Newly Diagnosed Uveal Melanoma

Melody Burchett discusses her journey with uveal melanoma and the formation of A Cure in Sight. This program was made possible with support from Immunocore.

After a brief introduction, Nathan L. Scott, M.D., gives an overview of uveal melanoma, including the risk factors and ways to help prevent it. This program was made possible with support from Immunocore.

Experts on chronic myeloid leukemia delve into the important role of informed shared decision-making in the optimal treatment of patients with CML.

Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.

Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.